Drug Profile

Research programme: parathyroid hormone 1 receptor agonists - Septerna

Alternative Names: PTH1R agonists- Septerna

Latest Information Update: 22 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Septerna
Class Small molecules
Mechanism of Action Parathyroid hormone receptor type 1 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hypoparathyroidism

Most Recent Events

11 Aug 2025 Septerna plans a clinical trial for PTH1R agonist in Hypoparathyroidism (PO) in the first half of 2026
30 Sep 2024 Updated pharmacodynamics data from preclinical studies in Hypoparathyroidism released by Septerna
03 Jun 2024 Septerna plans a phase I trial for Hypoparathyroidism (In-volunteers) in late 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com